HC Wainwright Predicts Precigen's Q1 Earnings (NASDAQ:PGEN)

Precigen, Inc. (NASDAQ:PGEN - Free Report) - Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Precigen in a report issued on Monday, July 14th. HC Wainwright analyst S. Ramakanth forecasts that the biotechnology company will earn ($0.02) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $6.00 target price on the stock. The consensus estimate for Precigen's current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Precigen's Q2 2026 earnings at ($0.01) EPS, Q3 2026 earnings at $0.00 EPS and Q4 2026 earnings at $0.02 EPS.

Other analysts have also recently issued reports about the company. JMP Securities reissued a "market outperform" rating and set a $6.00 price target on shares of Precigen in a report on Thursday, June 12th. Wall Street Zen upgraded Precigen from a "sell" rating to a "hold" rating in a research report on Saturday, July 12th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Precigen in a research report on Thursday, May 15th.

Precigen Trading Down 2.5%

Shares of PGEN traded down $0.05 during mid-day trading on Tuesday, reaching $1.78. The company's stock had a trading volume of 1,471,321 shares, compared to its average volume of 1,474,009. The stock has a market cap of $523.94 million, a P/E ratio of -3.17 and a beta of 1.78. The business has a 50-day simple moving average of $1.50 and a two-hundred day simple moving average of $1.51. Precigen has a 1-year low of $0.65 and a 1-year high of $2.17.

Precigen (NASDAQ:PGEN - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01. Precigen had a negative return on equity of 279.20% and a negative net margin of 3,728.87%. The business had revenue of $1.34 million during the quarter, compared to the consensus estimate of $0.50 million.

Institutional Investors Weigh In On Precigen

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Envestnet Asset Management Inc. grew its position in Precigen by 29.0% during the 4th quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 5,915 shares during the last quarter. Invesco Ltd. grew its position in shares of Precigen by 14.6% in the 4th quarter. Invesco Ltd. now owns 47,307 shares of the biotechnology company's stock valued at $53,000 after buying an additional 6,040 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Precigen by 12.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 81,610 shares of the biotechnology company's stock valued at $122,000 after buying an additional 9,043 shares during the last quarter. ProShare Advisors LLC grew its position in shares of Precigen by 26.6% in the 4th quarter. ProShare Advisors LLC now owns 51,822 shares of the biotechnology company's stock valued at $58,000 after buying an additional 10,900 shares during the last quarter. Finally, Wells Fargo & Company MN grew its position in shares of Precigen by 12.0% in the 4th quarter. Wells Fargo & Company MN now owns 114,558 shares of the biotechnology company's stock valued at $128,000 after buying an additional 12,285 shares during the last quarter. Institutional investors own 33.51% of the company's stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.